Price
CHART BY
Frequently asked questions
What is Absci's market capitalization?
The market capitalization of Absci is $1.48B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Absci?
Absci's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.80. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Absci's stock?
Currently, 11 analysts cover Absci's stock, with a consensus target price of $14.40. Analyst ratings provide insights into the stock's expected performance.
What is Absci's revenue over the trailing twelve months?
Over the trailing twelve months, Absci reported a revenue of $1.56M.
What is the EBITDA for Absci?
Absci's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$120.21M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Absci?
Absci has a free cash flow of -$108.97M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Absci have, and what sector and industry does it belong to?
Absci employs approximately 140 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Absci's shares?
The free float of Absci is 147.80M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $1.48B
- EPS (TTM)
- -$0.80
- Free Float
- 147.80M
- Revenue (TTM)
- $1.56M
- EBITDA (TTM)
- -$120.21M
- Free Cashflow (TTM)
- -$108.97M
Pricing
- 52W span
- $2.245$12.06
Analyst Ratings
The price target is $14.40 and the stock is covered by 11 analysts.
Buy
10
Hold
1
Sell
0
Information
Absci Corp. engages in drug discovery with generative design to create biologics for patients. Its platform combines AI models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. The firm has its own pipeline of AI designed therapeutics including ABS-201 and ABS-202. Absci Corp was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.
- Employees
- 140
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- ABSI
Fundamentals & EOD data from FactSet